指南与共识心力衰竭与心肌病

2020 AHA/ACC肥厚型心肌病诊断与治疗指南执行摘要

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
指南 / 共识 · J Am Coll Cardiol · 2020-11-20

该执行摘要基于2010至2020年文献综述,为成人和儿童肥厚型心肌病患者提供诊断与管理推荐及流程。内容涵盖诊断检查、遗传与家族筛查、风险分层、生活方式调整、手术与导管干预及药物治疗,构成指南导向的医疗治疗。

要点

  • 更新了先前肥厚型心肌病指南的许多推荐,纳入新证据或对早期证据的更好理解。
  • 执行摘要将完整指南的推荐操作化,组合诊断检查、遗传与家族筛查、风险分层等要素。
  • 药物治疗需参照产品说明书中的剂量、禁忌和药物相互作用。

核心结论

  • 执行摘要为成人和儿童肥厚型心肌病患者提供诊断与管理推荐及算法,以鼓励临床使用。

研究设计与样本

  • 制定机构为美国心脏病学会/美国心脏协会联合委员会;基于2010年1月1日至2020年4月30日的综合文献检索,涵盖PubMed、EMBASE、Cochrane协作网、AHRQ报告等数据库的英文人类研究、综述及其他证据。

关键数值与推荐

  • 推荐涵盖诊断检查、遗传与家族筛查、风险分层方法、生活方式调整、手术与导管干预以及药物治疗。
  • 指南导向药物治疗和其他推荐药物治疗方案中,读者应遵循产品说明书中的剂量、禁忌和药物相互作用。

临床怎么用

  • 临床医生可依据执行摘要中的推荐和算法诊断与管理成人和儿童肥厚型心肌病患者。
  • 实施指南导向药物治疗时,需依据产品说明书确定剂量、禁忌和药物相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. METHODS: A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. STRUCTURE: Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020. PMID: 33229115. doi:10.1016/j.jacc.2020.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。